Results 1 to 10 of about 29,137 (174)
The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma
Molecular Cell, 2022 Summary Mammalian SWI/SNF (mSWI/SNF or BAF) ATP-dependent chromatin remodeling complexes play critical roles in governing genomic architecture and gene expression and are frequently perturbed in human cancers.
Davis Ingram +2 more
exaly +2 more sources
Giant mesenteric myxoid liposarcoma: Challenges of diagnosis and treatment
Radiology Case Reports, 2022 Myxoid liposarcoma is the most frequent form of liposarcoma, frequently localized in the extremities. Abdominal liposarcomas more commonly arise from the retroperitoneum. However, primary mesenteric localization is extremely rare.
Ghizlane Rais
exaly +2 more sources
Management of myxoid liposarcoma of the extremity
Oncology letters, 2021 Myxoid liposarcoma (MLPS) is the second most common type of LPS after the well differentiated LPS. MLPS is primarily localized to the extremities. The incidence of LPS is ~2 per million worldwide. MLPS accounts for ~30% of all LPS cases.
Yehia Tfayli +3 more
semanticscholar +3 more sources
Primary Orbital Myxoid Liposarcoma. [PDF]
Med Sci (Basel), 2023 Although liposarcoma is the most prevalent soft tissue sarcoma in adults, head and neck liposarcomas are rare and account for less than 5% of all liposarcomas. The primary orbital location is even more exceptional, with fewer than 100 cases documented in the medical literature.
Benavides-Huerto MA +3 more
europepmc +5 more sources
Myxoid liposarcoma. Experience with chemotherapy [PDF]
Cancer, 1994 Myxoid liposarcoma (ML) is the most common type of liposarcoma. It has been classified as an intermediate grade tumor with a definite metastatic potential but a relatively indolent natural history. Little is known about its sensitivity to chemotherapy.The authors reviewed their experience with chemotherapy in ML from 1986 to 1992.
Shreyaskumar Patel +2 more
exaly +3 more sources
Surgical Outcomes and Prognostic Factors of Myxoid Liposarcoma in Extremities: A Retrospective Study
Orthopaedic Surgery, 2019 To evaluate treatments and prognostic factors for the myxoid liposarcoma in extremities.
Kai Zheng, Ming Xu
exaly +2 more sources
JAMA Oncology, 2023 Importance Preclinical data about the synergistic activity of radiotherapy (RT) and trabectedin have been reported. The combination of trabectedin and RT in treating myxoid liposarcomas appears worth exploring.
R. Sanfilippo +20 more
semanticscholar +1 more source
Prognostic value of nuclear morphometry in myxoid liposarcoma
Cancer Science, 2023 Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by ...
K. Kawaguchi +8 more
semanticscholar +1 more source
Patterns of Metastatic Recurrence of Genetically Confirmed Myxoid Liposarcoma
Annals of Surgical Oncology, 2023 Most sarcomas metastasize predominantly to the lungs, and chest x-ray, or computed tomography, is the most commonly used staging investigation. Myxoid liposarcomas (MLSs) are rare tumors with a tendency to metastasize to extrapulmonary loci.
P. Homsy +5 more
semanticscholar +1 more source
Oncogenesis, 2022 Myxoid liposarcoma (MLS) represents a common subtype of liposarcoma molecularly characterized by a recurrent chromosomal translocation that generates a chimeric FUS-DDIT3 fusion gene.
Ruth Berthold +13 more
semanticscholar +1 more source